US Patent

US12186306 — Methods of treatment for cystic fibrosis

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2043-01-10 · 17y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating cystic fibrosis or a CFTR mediated disease by administering Compound I or a pharmaceutically acceptable salt thereof.

USPTO Abstract

This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof.The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4088`	—

Patent Metadata

Patent number: US12186306
Jurisdiction: US
Classification: Method of Use
Expires: 2043-01-10
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.